BACH2 switch raises fetal haemoglobin in cell experiments
Researchers found a new way to turn on fetal haemoglobin, the blood protein that can ease sickle cell disease and beta thalassaemia. Genetic comparisons in 28,279 people pointed to BACH2; cell experiments then showed that reducing it lets NRF2 activate the relevant genes. The pathway differs from BCL11A, a target already used in treatment. No BACH2 intervention has been tested in patients.
Science··Night
Genetic signal points to BACH2
A study published in Nature on September 30 identified BACH2 as a regulator of fetal haemoglobin. Independent reporting by Genetic Engineering & Biotechnology News described the same finding and its possible relevance to inherited blood disorders. Fetal haemoglobin normally declines after birth, but higher levels in adulthood can ease symptoms of sickle cell disease and beta thalassaemia. The researchers compared genetic variants with fetal-haemoglobin levels in 28,279 people of several ancestry groups. They found 91 independent associations in 12 genomic regions; one variant tracked with lower BACH2 activity and higher fetal haemoglobin. That human comparison identified an association and a target for experiments, rather than a tested medicine.[1], [2]
Cell experiments reveal the switch
The team then lowered or inhibited BACH2 directly in cell experiments. Fetal-haemoglobin production increased. Molecular tests showed how the change works: BACH2 normally restrains the gamma-globin genes, which encode components of fetal haemoglobin. When that restraint eased, NRF2 bound more strongly near those genes and helped activate them. The researchers also altered the partly overlapping DNA binding sequences used by BACH2 and NRF2 separately, shifting gene activity in different directions. Those interventions give the proposed mechanism support beyond the population association. They establish a response in cells, however, and do not measure clinical outcomes or long-term safety in people.[1]
A separate path from BCL11A
The BACH2–NRF2 route operated independently of BCL11A, a regulator already targeted by a gene-editing treatment for sickle cell disease. That distinction gives researchers another molecular route to investigate, including whether both pathways can be altered without unwanted effects. The newly identified route has not been used as a treatment in patients, and the study did not establish a safe dose or a durable increase in fetal haemoglobin after a BACH2 intervention. The human genetic comparison and laboratory manipulation answer different parts of the question: the first links variation to blood-protein levels, while the second shows that changing the regulator can move production in cells. Clinical work would have to assess whether those changes are useful in living patients.[1]
Related columns
For more information on this topic, you can read the related columns.
